BACKGROUND: Uterine serous carcinoma (USC) is a subtype of endometrial cancer associated with chemoresistance and poor outcome. Overexpression of tubulin-β-III and p-glycoprotein has been linked to paclitaxel resistance in many cancers but has been undercharacterized among USCs. Epothilones have demonstrated activity in certain paclitaxel-resistant malignancies. In this study, relationships are clarified, in USCs relative to ovarian serous carcinomas (OSCs), between tubulin-β-III and p-glycoprotein expression, clinical outcome, and in vitro chemoresponsiveness to epothilone B, ixabepilone, and paclitaxel. METHODS: Tubulin-β-III and p-glycoprotein were quantified by real-time polymerase chain reaction in 48 fresh-frozen tissue samples and 13 cell lines. Copy number was correlated with immunohistochemistry and overall survival. Median inhibitory concentration (IC50 ) was determined using viability and metabolic assays. Impact of tubulin-β-III knockdown on IC50 was assessed with small interfering RNAs. RESULTS: USC overexpressed tubulin-β-III but not p-glycoprotein relative to OSC in both fresh-frozen tissues (552.9 ± 106.7 versus 202.0 ± 43.99, P = .01) and cell lines (1701.0 ± 376.4 versus 645.1 ± 157.9, P = .02). Tubulin-β-III immunohistochemistry reflected quantitative real-time polymerase chain reaction copy number and overexpression stratified patients by overall survival (copy number ≤ 400: 615 days; copy number > 400: 165 days, P = .049); p-glycoprotein did not predict clinical outcome. USCs remained exquisitely sensitive to patupilone in vitro despite tubulin-β-III overexpression (IC50,USC 0.245 ± 0.11 nM versus IC50,OSC 1.01 ± 0.13 nM, P = .006). CONCLUSIONS: Tubulin-β-III overexpression in USCs discriminates poor prognosis, serves as a marker for sensitivity to epothilones, and may contribute to paclitaxel resistance. Immunohistochemistry reliably identifies tumors with overexpression of tubulin-β-III, and a subset of individuals likely to respond to patupilone and ixabepilone. Epothilones warrant clinical investigation for treatment of USCs.
BACKGROUND: Uterine serous carcinoma (USC) is a subtype of endometrial cancer associated with chemoresistance and poor outcome. Overexpression of tubulin-β-III and p-glycoprotein has been linked to paclitaxel resistance in many cancers but has been undercharacterized among USCs. Epothilones have demonstrated activity in certain paclitaxel-resistant malignancies. In this study, relationships are clarified, in USCs relative to ovarian serous carcinomas (OSCs), between tubulin-β-III and p-glycoprotein expression, clinical outcome, and in vitro chemoresponsiveness to epothilone B, ixabepilone, and paclitaxel. METHODS: Tubulin-β-III and p-glycoprotein were quantified by real-time polymerase chain reaction in 48 fresh-frozen tissue samples and 13 cell lines. Copy number was correlated with immunohistochemistry and overall survival. Median inhibitory concentration (IC50 ) was determined using viability and metabolic assays. Impact of tubulin-β-III knockdown on IC50 was assessed with small interfering RNAs. RESULTS: USC overexpressed tubulin-β-III but not p-glycoprotein relative to OSC in both fresh-frozen tissues (552.9 ± 106.7 versus 202.0 ± 43.99, P = .01) and cell lines (1701.0 ± 376.4 versus 645.1 ± 157.9, P = .02). Tubulin-β-III immunohistochemistry reflected quantitative real-time polymerase chain reaction copy number and overexpression stratified patients by overall survival (copy number ≤ 400: 615 days; copy number > 400: 165 days, P = .049); p-glycoprotein did not predict clinical outcome. USCs remained exquisitely sensitive to patupilone in vitro despite tubulin-β-III overexpression (IC50,USC 0.245 ± 0.11 nM versus IC50,OSC 1.01 ± 0.13 nM, P = .006). CONCLUSIONS: Tubulin-β-III overexpression in USCs discriminates poor prognosis, serves as a marker for sensitivity to epothilones, and may contribute to paclitaxel resistance. Immunohistochemistry reliably identifies tumors with overexpression of tubulin-β-III, and a subset of individuals likely to respond to patupilone and ixabepilone. Epothilones warrant clinical investigation for treatment of USCs.
Authors: Ingrid Vandenput; An Capoen; Lieve Coenegrachts; Godelieve Verbist; Philippe Moerman; Ignace Vergote; Frédéric Amant Journal: Int J Gynecol Cancer Date: 2011-08 Impact factor: 3.437
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: Dana M Roque; Natalia Buza; Michelle Glasgow; Stefania Bellone; Ileana Bortolomai; Sara Gasparrini; Emiliano Cocco; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin Journal: Clin Exp Metastasis Date: 2013-09-05 Impact factor: 5.150
Authors: Carolyn K McCourt; Wei Deng; Don S Dizon; Heather A Lankes; Michael J Birrer; Michele M Lomme; Matthew A Powell; James E Kendrick; Joel N Saltzman; David Warshal; Meaghan E Tenney; David M Kushner; Carol Aghajanian Journal: Gynecol Oncol Date: 2016-10-28 Impact factor: 5.482
Authors: Yang Deng; Fan Yang; Emiliano Cocco; Eric Song; Junwei Zhang; Jiajia Cui; Muneeb Mohideen; Stefania Bellone; Alessandro D Santin; W Mark Saltzman Journal: Proc Natl Acad Sci U S A Date: 2016-09-23 Impact factor: 11.205
Authors: David M Peereboom; Conleth Murphy; Manmeet S Ahluwalia; Alison Conlin; April Eichler; Catherine Van Poznak; Joseph Baar; Paul Elson; Andrew D Seidman Journal: Neuro Oncol Date: 2014-01-26 Impact factor: 12.300
Authors: Melissa J Davis; Brandon J Wainwright; Laura A Genovesi; Amanda Millar; Elissa Tolson; Matthew Singleton; Emily Hassall; Marija Kojic; Caterina Brighi; Emily Girard; Clara Andradas; Mani Kuchibhotla; Dharmesh D Bhuva; Raelene Endersby; Nicholas G Gottardo; Anne Bernard; Christelle Adolphe; James M Olson; Michael D Taylor Journal: Genome Med Date: 2021-06-21 Impact factor: 11.117